Physician profile
Brian M Lake
NPI 1295887040
$887,600.32
in general payments reported to CMS, 2019-2025
66 companies · $162K in 2025
The $162K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110K · 2020: $95K · 2021: $118K · 2022: $102K · 2023: $137K · 2024: $163K · 2025: $162K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $367K · Travel and Lodging: $33K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $30K · Food and Beverage: $23K · Consulting Fee: $11K · Education: $52.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $366,584.22 |
| Travel and Lodging | $32,527.64 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $30,149.00 |
| Food and Beverage | $22,630.35 |
| Consulting Fee | $10,500.00 |
| Education | $52.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $295,767.40 | 2019-2025 | Mounjaro, Lyumjev, Jardiance |
| Novo Nordisk INC | $198,395.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $151,610.40 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Medtronic, INC. | $68,996.86 | 2021-2025 | Minimed 780g |
| Medtronic Minimed, INC. | $46,788.98 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $45,492.36 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $35,519.69 | 2019-2023 | Farxiga |
| Tandem Diabetes Care, INC. | $15,852.10 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $13,586.94 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Cequr Corporation | $5,356.60 | 2023-2025 | Cequr Simplicity |
| Insulet Corporation | $2,051.80 | 2020-2025 | Omnipod, Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $1,045.46 | 2021-2025 | |
| Amgen INC. | $836.48 | 2019-2025 | Evenity, Tepezza, Prolia |
| Novartis Pharmaceuticals Corporation | $481.29 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $475.33 | 2019-2025 | Jardiance |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lake listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.